Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CN1-H55D3 | Human | Human CNR1 Protein, Flag,His Tag (Detergent) |  |
|
|
| CN1-H52P6 | Human | Human CNR1 Full Length Protein (VLP) |
|
Anti-CNR1 Antibody, Human IgG4 captured on Protein A Chip can bind Human CNR1 Protein, Flag,His Tag (Cat. No. CN1-H55D3) with an affinity constant of 42.8 nM as determined in a SPR assay (in presence of LMNG and CHS) (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Cannabidiol/Dronabinol | THC-5; delta-9-THC/CBD; MPL-001; MPL-005; GW-1000; KL16-012; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT | Approved | Gw Pharmaceuticals | Sativex, Qixleef | Canada | Muscle Spasticity; Neuralgia; Cancer Pain; Chronic Pain; Multiple Sclerosis | null | 2005-04-01 | Dementia; Panic Disorder; Phobia, Social; Neuralgia, Postherpetic; Huntington Disease; Reflex Sympathetic Dystrophy; Tourette Syndrome; Muscle Spasticity; Malnutrition; Sciatica; Acute Pain; Neuromyelitis Optica; Arthritis, Psoriatic; Neuralgia; Urinary Bladder, Overactive; Back Pain; Osteoarthritis, Knee; Hepatic Insufficiency; Stress Disorders, Post-Traumatic; Healthy Aging; Hidradenitis Suppurativa; Agoraphobia; Drug Resistant Epilepsy; Renal Insufficiency, Chronic; Social Behavior; Corticobasal degeneration; Cerebral Palsy; Low Back Pain; Agitation; Sleep Initiation and Maintenance Disorders; Peripheral Nervous System Diseases; Genital Diseases, Male; Pain; Chronic Pain; Depression; Depressive Disorder, Major; Marijuana Abuse; Marijuana Use; Spasm; Squamous Cell Carcinoma of Head and Neck; Cancer Pain; Renal Insufficiency; Migraine Disorders; Spinal Cord Injuries; Neoplasms; Arthritis, Rheumatoid; Neck Pain; Diabetic Neuropathies; Sleep Wake Disorders; Opioid-Related Disorders; Essential Tremor; Anorexia; | Details |
| Cannabidiol | AVCN-583601; GLA-015; BTX-1503; BTX-1801; BTX-1702; LYT-310; RAD011; PBX-1308; RAD-011; BRCX-014; RLS-103; GWP-42003; GWP-42003-P; BOL-DP-o-05; GW-42003; BTX-1204; ZYN-002; PTL-101; CHI-902; APH-1501 | Approved | Gw Pharmaceuticals Plc | Epidiolex, Epidyolex, Zygel, Cannepil | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Tobacco Smoking; Migraine Disorders; Peripheral Nervous System Diseases; Acne Vulgaris; HIV Infections; Ovarian Neoplasms; Sleep Initiation and Maintenance Disorders; Facial Pain; Substance-Related Disorders; Marijuana Smoking; Tobacco Use Cessation; Seizures; Tuberous Sclerosis; Pain; Schizophrenia; Chronic Pain; Marijuana Use; Anxiety; Rett Syndrome; Appetitive Behavior; Autism Spectrum Disorder; Marijuana Abuse; Brain Injuries, Traumatic; Depression; Alcoholic Intoxication; Inflammatory Bowel Diseases; Fatty Liver; Child Behavior Disorders; Diabetes Mellitus, Type 2; Spinal Cord Injuries; Muscle injury; Neoplasms; Psychotic Disorders; Opioid-Related Disorders; Diabetic Neuropathies; Coronavirus Disease 2019 (COVID-19); Musculoskeletal Pain; Anxiety Disorders; Sleep Wake Disorders; Graft vs Host Disease; Blepharospasm; Dyspepsia; Arthritis, Rheumatoid; Hyperalgesia; Chronic Urticaria; Hoarding Disorder; Bipolar Disorder; Pancreatic Neoplasms; Brain Diseases; Dysmenorrhea; Sturge-Weber Syndrome; Memory; Mult | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotechnologies Inc | Neoplasms; Nutrition Disorders; Child Nutrition Disorders; Vomiting; Nausea; Cachexia; Sarcopenia; Anorexia Nervosa | Details | |
| Adezunap | AP-707 | Phase 3 Clinical | CannaXan GmbH | Stroke; Peripheral Nerve Injuries; Diabetes Mellitus; Low Back Pain; Accidental Injuries; Diabetic peripheral neuropathy; Neuralgia; Back Pain; Phantom Limb; Multiple Sclerosis; Peripheral Nervous System Diseases; Brachial Plexus Neuropathies; Somatoform Disorders; Diabetic Neuropathies; Pain, Postoperative; Paraplegia; Chronic Pain; Brain Injuries, Traumatic; Pain | Details |
| Dronabinol（Vertanical） | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | Details |
| cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Coronavirus Disease 2019 (COVID-19); Pericarditis; Cardiovascular Diseases; Myocarditis | Details | |
| V-24343 | V-24343; ANEB-001 | Phase 2 Clinical | Vernalis Plc | Poisoning; Obesity | Details |
| 11C-MePPEP | 11C-MePPEP | Phase 2 Clinical | Eli Lilly And Company | Substance-Related Disorders; Obesity | Details |
| AX-1602 | AX-1602 | Phase 2 Clinical | Axim Biotechnologies Inc | Psoriasis; Dermatitis, Atopic; Vitiligo | Details |
| Nimacimab | RYI-018; RYI-028; JNJ-2463 | Phase 2 Clinical | Bird Rock Bio Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Renal Insufficiency, Chronic; Diabetic Gastroparesis | Details |
| ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Weight Loss; Pain; Anorexia; Cachexia; Low Back Pain | Details |
| AEF-0217 | AEF-0217 | Phase 2 Clinical | Aelis Farma | Down Syndrome | Details |
| Monlunabant | S-MRI-1891; (-)-MRI-1891; NN9440–INV-202; INV-202; MRI-1891 | Phase 2 Clinical | Inversago Pharma Inc | Metabolic Syndrome; Metabolic Diseases; Diabetic Nephropathies; Obesity | Details |
| C20T5 | C20T5 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| C12T12 | C12T12 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
| Tetrahydrocannabinol valine hemisuccinate (Skye Bioscience) | NB-1111; Sb-100 OE; SBI-100 OE; THC-VHS-NEC; THCVHS; SBI-100; THCVHS-N; UM-5050; THCVHS-NE | Phase 2 Clinical | University Of Mississippi | Glaucoma, Open-Angle; Glaucoma; Ocular Hypertension | Details |
| IGC-AD1 | IGC-AD1 | Phase 2 Clinical | University Of South Florida | Dementia; Psychomotor Agitation; Alzheimer Disease | Details |
| AEF-0117 | AEF-0117 | Phase 2 Clinical | National Institute On Drug Abuse, Aelis Farma | Marijuana Abuse | Details |
| [11C]OMAR | [11C]JHU-75528 | Phase 1 Clinical | Johns Hopkins University School Of Medicine | Schizophrenia; Marijuana Abuse | Details |
| ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Neuralgia; Fibromyalgia | Details |
| Tetrahydrocannabivarin | GWP-42004; THCV; O-4394; DELTA9-THCV; GW-42004 | Phase 1 Clinical | Gw Pharmaceuticals Plc | Diabetes Mellitus, Type 2; Metabolic Syndrome; Obesity, Morbid; Hypercholesterolemia; Hyperglycemia; Dyslipidemias | Details |
| Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 1 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | Details |
| Zevaquenabant | MRI-1867; (S)-MRI-1867; INV-101 | Phase 1 Clinical | National Institutes Of Health | Scleroderma, Systemic | Details |
| Atorvastatin Calcium Hydrate/Cannabidiol | Phase 1 Clinical | Indication Bioscience LLC | Coronary Disease; Dyslipidemias | Details | |
| TPT0301 | TPT-0301; TPT0301 | Phase 1 Clinical | Tetra Pharm Technologies ApS | Chronic Pain | Details |
| INV-347 | NN9441; NN-9441; INV-347 | Phase 1 Clinical | Inversago Pharma Inc | Obesity | Details |
| IPI 201（Isosceles Pharmaceuticals Inc ） | IPI-201 | Phase 1 Clinical | Pain, Postoperative | Details | |
| GFB-024 | Phase 1 Clinical | Takeda Pharma | Kidney Diseases; Endocrine System Diseases; Diabetes Complications; Diabetic Nephropathies; Diabetes Mellitus | Details | |
| DBPR-211 | Phase 1 Clinical | National Health Research Institutes | Diabetes Mellitus, Type 2 | Details | |
| MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | Details |
| MP-20X | MP-20X | Clinical | Medipure Holdings | Mood Disorders; Anxiety Disorders | Details |
| Cannabidiol (Receptor Life Sciences) | Clinical | Receptor Life Sciences Inc | Autism Spectrum Disorder | Details | |
| Cannabidiol/Palmitoylethanolamide | THX-210; SCI–210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | Details |
This web search service is supported by Google Inc.
A-Z
